Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
A targeted treatment with anti-CD19 CAR T-cells results in different responses
PDL1 and CD38 antigen expression in NSCLC
The rise of MRD in multiple myeloma: could this be an answer to a cure?
Developments in CML over the past 30 years and where we are today